Neurosurgery:血管内栓塞未破裂脑AVM还不如保守治疗好!

2018-05-26 杨中华 脑血管病及重症文献导读

传统上讲,血管内栓塞是显微外科或放射外科治疗脑动静脉畸形(AVM)的辅助手段。然而,随着血管内治疗方法的改进,越来越多的人认为血管内栓塞可以作为治疗脑AVM的方法。但是,对于较小、表浅、栓塞风险较低的AVM,血管内治疗的栓塞率仍然明显低于显微外科手术或放射手术。尽管血管内治疗的病例分析研究发现闭塞率逐渐提高,但是这些研究报道的闭塞率(从2.3%-100%)和死亡率(0%-22.2%)差异很大,提示

传统上讲,血管内栓塞是显微外科或放射外科治疗脑动静脉畸形(AVM)的辅助手段。然而,随着血管内治疗方法的改进,越来越多的人认为血管内栓塞可以作为治疗脑AVM的方法。但是,对于较小、表浅、栓塞风险较低的AVM,血管内治疗的栓塞率仍然明显低于显微外科手术或放射手术。尽管血管内治疗的病例分析研究发现闭塞率逐渐提高,但是这些研究报道的闭塞率(从2.3%-100%)和死亡率(0%-22.2%)差异很大,提示存在偏倚。此外,大部分研究的随访时间较短,将无法充分阐明AVM的长期出血风险。ARUBA试验发现保守的AVM管理方案优于血管内栓塞,但是该研究设计和实施存在争论。

2018年4月来自霍普金斯医科大学神经外科的Wuyang Yang等在NEUROSURGERY上公布了他们的研究结果,目的在于比较血管内栓塞和保守治疗的长期的相对风险和获益(出血和功能预后)。

该研究回顾性复习了1990到2013年间他们中心的颅内AVM患者。纳入的患者为仅进行了栓塞手术而未进行其他手术治疗的患者以及保守治疗的患者。

共205例患者符合纳入标准,160例为非干预组,45例为栓塞组。全部患者的平均年龄为40.2 +- 19.5岁,栓塞组年轻患者更多(P = 0.026)。保守组和栓塞组表现为出血的患者分别为31.9%(51例)和28.9%(13例)(P = 0.703)。两组间其他基线特征类似。

在平均7.7年的随访中,共30例(14.6%)随访期间发生出血。多变量Cox回归显示老年(P = 0.031)和表现为出血(P < 0.001)与随访时发生出血显著相关。未破裂AVM的亚组分析发现,血管内栓塞的出血危害比是保守治疗的4倍(P = 0.044)。

最终作者认为老年和表现为出血与随访期间出血风险增加有关。仅采用单一的血管内栓塞治疗方案会增加出血的风险(vs.保守治疗),特别是未破裂AVM。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2039473, encodeId=47f120394e3fb, content=<a href='/topic/show?id=5ca5304262' target=_blank style='color:#2F92EE;'>#AVM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3042, encryptionId=5ca5304262, topicName=AVM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sat Dec 15 08:54:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877725, encodeId=a1e718e772581, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Tue Nov 13 22:54:00 CST 2018, time=2018-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021626, encodeId=7c61202162690, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Oct 03 11:54:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319476, encodeId=84783194e675, content=很有意思的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff401643028, createdName=Dr. Shark, createdTime=Mon May 28 23:06:16 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364343, encodeId=cdbc1364343ea, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon May 28 01:54:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508912, encodeId=ed4d150891201, content=<a href='/topic/show?id=8e1e2e181f4' target=_blank style='color:#2F92EE;'>#保守治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27181, encryptionId=8e1e2e181f4, topicName=保守治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d710016703, createdName=cmsvly, createdTime=Mon May 28 01:54:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318722, encodeId=cf00318e228b, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat May 26 11:29:11 CST 2018, time=2018-05-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2039473, encodeId=47f120394e3fb, content=<a href='/topic/show?id=5ca5304262' target=_blank style='color:#2F92EE;'>#AVM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3042, encryptionId=5ca5304262, topicName=AVM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sat Dec 15 08:54:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877725, encodeId=a1e718e772581, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Tue Nov 13 22:54:00 CST 2018, time=2018-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021626, encodeId=7c61202162690, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Oct 03 11:54:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319476, encodeId=84783194e675, content=很有意思的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff401643028, createdName=Dr. Shark, createdTime=Mon May 28 23:06:16 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364343, encodeId=cdbc1364343ea, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon May 28 01:54:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508912, encodeId=ed4d150891201, content=<a href='/topic/show?id=8e1e2e181f4' target=_blank style='color:#2F92EE;'>#保守治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27181, encryptionId=8e1e2e181f4, topicName=保守治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d710016703, createdName=cmsvly, createdTime=Mon May 28 01:54:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318722, encodeId=cf00318e228b, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat May 26 11:29:11 CST 2018, time=2018-05-26, status=1, ipAttribution=)]
    2018-11-13 chg121
  3. [GetPortalCommentsPageByObjectIdResponse(id=2039473, encodeId=47f120394e3fb, content=<a href='/topic/show?id=5ca5304262' target=_blank style='color:#2F92EE;'>#AVM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3042, encryptionId=5ca5304262, topicName=AVM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sat Dec 15 08:54:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877725, encodeId=a1e718e772581, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Tue Nov 13 22:54:00 CST 2018, time=2018-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021626, encodeId=7c61202162690, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Oct 03 11:54:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319476, encodeId=84783194e675, content=很有意思的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff401643028, createdName=Dr. Shark, createdTime=Mon May 28 23:06:16 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364343, encodeId=cdbc1364343ea, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon May 28 01:54:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508912, encodeId=ed4d150891201, content=<a href='/topic/show?id=8e1e2e181f4' target=_blank style='color:#2F92EE;'>#保守治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27181, encryptionId=8e1e2e181f4, topicName=保守治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d710016703, createdName=cmsvly, createdTime=Mon May 28 01:54:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318722, encodeId=cf00318e228b, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat May 26 11:29:11 CST 2018, time=2018-05-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2039473, encodeId=47f120394e3fb, content=<a href='/topic/show?id=5ca5304262' target=_blank style='color:#2F92EE;'>#AVM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3042, encryptionId=5ca5304262, topicName=AVM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sat Dec 15 08:54:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877725, encodeId=a1e718e772581, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Tue Nov 13 22:54:00 CST 2018, time=2018-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021626, encodeId=7c61202162690, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Oct 03 11:54:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319476, encodeId=84783194e675, content=很有意思的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff401643028, createdName=Dr. Shark, createdTime=Mon May 28 23:06:16 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364343, encodeId=cdbc1364343ea, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon May 28 01:54:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508912, encodeId=ed4d150891201, content=<a href='/topic/show?id=8e1e2e181f4' target=_blank style='color:#2F92EE;'>#保守治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27181, encryptionId=8e1e2e181f4, topicName=保守治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d710016703, createdName=cmsvly, createdTime=Mon May 28 01:54:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318722, encodeId=cf00318e228b, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat May 26 11:29:11 CST 2018, time=2018-05-26, status=1, ipAttribution=)]
    2018-05-28 Dr. Shark

    很有意思的研究

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2039473, encodeId=47f120394e3fb, content=<a href='/topic/show?id=5ca5304262' target=_blank style='color:#2F92EE;'>#AVM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3042, encryptionId=5ca5304262, topicName=AVM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sat Dec 15 08:54:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877725, encodeId=a1e718e772581, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Tue Nov 13 22:54:00 CST 2018, time=2018-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021626, encodeId=7c61202162690, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Oct 03 11:54:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319476, encodeId=84783194e675, content=很有意思的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff401643028, createdName=Dr. Shark, createdTime=Mon May 28 23:06:16 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364343, encodeId=cdbc1364343ea, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon May 28 01:54:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508912, encodeId=ed4d150891201, content=<a href='/topic/show?id=8e1e2e181f4' target=_blank style='color:#2F92EE;'>#保守治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27181, encryptionId=8e1e2e181f4, topicName=保守治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d710016703, createdName=cmsvly, createdTime=Mon May 28 01:54:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318722, encodeId=cf00318e228b, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat May 26 11:29:11 CST 2018, time=2018-05-26, status=1, ipAttribution=)]
    2018-05-28 lsndxfj
  6. [GetPortalCommentsPageByObjectIdResponse(id=2039473, encodeId=47f120394e3fb, content=<a href='/topic/show?id=5ca5304262' target=_blank style='color:#2F92EE;'>#AVM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3042, encryptionId=5ca5304262, topicName=AVM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sat Dec 15 08:54:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877725, encodeId=a1e718e772581, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Tue Nov 13 22:54:00 CST 2018, time=2018-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021626, encodeId=7c61202162690, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Oct 03 11:54:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319476, encodeId=84783194e675, content=很有意思的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff401643028, createdName=Dr. Shark, createdTime=Mon May 28 23:06:16 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364343, encodeId=cdbc1364343ea, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon May 28 01:54:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508912, encodeId=ed4d150891201, content=<a href='/topic/show?id=8e1e2e181f4' target=_blank style='color:#2F92EE;'>#保守治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27181, encryptionId=8e1e2e181f4, topicName=保守治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d710016703, createdName=cmsvly, createdTime=Mon May 28 01:54:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318722, encodeId=cf00318e228b, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat May 26 11:29:11 CST 2018, time=2018-05-26, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2039473, encodeId=47f120394e3fb, content=<a href='/topic/show?id=5ca5304262' target=_blank style='color:#2F92EE;'>#AVM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3042, encryptionId=5ca5304262, topicName=AVM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sat Dec 15 08:54:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877725, encodeId=a1e718e772581, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Tue Nov 13 22:54:00 CST 2018, time=2018-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021626, encodeId=7c61202162690, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Oct 03 11:54:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319476, encodeId=84783194e675, content=很有意思的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff401643028, createdName=Dr. Shark, createdTime=Mon May 28 23:06:16 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364343, encodeId=cdbc1364343ea, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon May 28 01:54:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508912, encodeId=ed4d150891201, content=<a href='/topic/show?id=8e1e2e181f4' target=_blank style='color:#2F92EE;'>#保守治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27181, encryptionId=8e1e2e181f4, topicName=保守治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d710016703, createdName=cmsvly, createdTime=Mon May 28 01:54:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318722, encodeId=cf00318e228b, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat May 26 11:29:11 CST 2018, time=2018-05-26, status=1, ipAttribution=)]
    2018-05-26 1ddf0692m34(暂无匿称)

    学习了.长知识

    0

相关资讯

这大概是他最后一次血栓栓塞了吧……

虽然房颤很普遍,连国内大型流行病学调查显示,其患病率接近百分之一,减少血栓栓塞并发症是重要的目标,故抗凝是房颤治疗的重要内容。但要在国内目前的医疗现状下做好这项工作,难度相当大。

超声诊断肺动脉血栓栓塞1例

患者,女,66岁。以双膝关节疼痛10年,加重伴活动受限2周之主诉入院。

这样的栓塞影像,你见过几次?

虽然房颤很普遍,连国内大型流行病学调查显示,其患病率接近百分之一,减少血栓栓塞并发症是重要的目标,故抗凝是房颤治疗的重要内容。但要在国内目前的医疗现状下做好这项工作,难度相当大。

Neurosurgery:破裂颅内动脉瘤栓塞术中使用替罗非班的安全性

血栓栓塞是颅内破裂动脉瘤弹簧圈栓塞术中最常见的并发症之一,特别是术中采用了支架并且未预先抗血小板治疗的患者。

JAMA Intern Med:感染性心内膜炎赘生物与栓塞风险

研究认为感染性心内膜炎赘生物大于10mm导致患者栓塞以及死亡风险显著增加

NEJM:下腔静脉滤器支柱栓塞-病例报道

该患者经血管内介入治疗取出下腔静脉滤器。在取出下腔静脉滤器之前病人侧腰疼痛只有在支持治疗下才能缓解。考虑到取出支柱干预的风险,决定将栓塞支柱不予取出。下腔静脉滤器断裂是这些装置潜在的并发症。